| 15374980 |
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
Rusnak, DW,
Wood, ER,
Lackey, K,
Yuan, D,
Horne, E,
Pennisi, C,
Gilmer, TM,
Dickerson, SH,
Shewchuk, L,
Alligood, KJ,
Truesdale, AT,
Hassell, A,
Ellis, B,
McDonald, OB
|
Cancer Res. |
2004 |
| 17575237 |
Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647
Jackman, L,
Ventura, R,
Shi, Y,
De Costa, A,
Zhang, W,
Keast, P,
Engell, K,
Wang, J,
Chen, J,
Yu, P,
Lutman, J,
Bentzien, F,
Laird, AD,
Joly, AH,
Meyer, SM,
Martini, JF,
Yakes, FM,
Gendreau, SB,
Jaeger, CT,
Cancilla, B,
Chu, F,
Aftab, DT
|
Clin. Cancer Res. |
2007 |
| 15256466 |
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity
Allegrini, PR,
McSheehy, P,
Mestan, J,
Traxler, P,
Fabbro, D,
Caravatti, G,
Brandt, R,
Wartmann, M,
Wood, J,
Brueggen, J,
Tang, C,
Meyer, T,
Lane, HA,
Cozens, R,
Grosios, K
|
Cancer Res. |
2004 |
| 12214266 |
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
Spector, NL,
Alligood, KJ,
Rusnak, DW,
Liu, LH,
Keith, BR,
Owens, G,
Ma, H,
Mullin, RJ,
Xia, W
|
Oncogene |
2002 |
| 17942920 |
Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor
Finn, RS,
Emerson, EO,
Campbell, M,
Steyn, SJ,
Pustilnik, LR,
Morris, J,
Bhattacharya, SK,
Kath, JC,
Connell, RD,
Rossi, AM,
Floyd, E,
Moyer, JD,
Coleman, KG,
Harriman, S,
Wagner, L,
Jani, JP,
Ralston, S,
Winter, SM,
Currier, N,
Rafidi, K
|
Cancer Res. |
2007 |
| 20145185 |
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer
Ogilvie, D,
Smith, P,
Speake, G,
Anderton, J,
Beck, S,
Wilkinson, RW,
Vincent, J,
Barlaam, B,
Hickinson, DM,
Klinowska, T,
Marshall, G,
Davenport, S,
Callis, R,
Trigwell, C,
Grosios, K,
Mills, E
|
Clin. Cancer Res. |
2010 |
| 28274957 |
An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer
Hyman, DM,
Solit, DB,
Nagy, R,
Sheehan, JH,
Sliwoski, GR,
Berger, MF,
He, J,
Lalani, AS,
Brewer, MR,
Miller, V,
Cross, D,
Cutler, RE,
Hanker, AB,
Lanman, R,
Arteaga, CL,
Koch, JP,
Lovly, CM,
Meiler, J
|
Cancer Discov |
2017 |
| 18408761 |
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Meyerson, M,
Li, D,
Wong, KK,
Ambrogio, L,
Chirieac, LR,
Takahashi, M,
Shimamura, T,
Shapiro, GI,
Baum, A,
Rettig, WJ,
Padera, RF,
Himmelsbach, F,
Solca, F,
Kubo, S,
Greulich, H
|
Oncogene |
2008 |
| 11278435 |
Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition
Nelson, JM,
Fry, DW
|
J. Biol. Chem. |
2001 |
| 15173008 |
Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase
Johnson, BD,
Overbeek, E,
Baxter, M,
Wissner, A,
Shen, R,
Wang, YF,
Tsou, HR,
Floyd, MB,
Discafani, CM,
Rabindran, SK,
Nilakantan, R,
Rosfjord, EC,
Golas, J,
Reich, MF,
Shi, X,
Hallett, WA
|
Cancer Res |
2004 |
